| INTRODUC TI ON
Lung cancer is the leading cause of cancer-related deaths worldwide among both men and women. 1 Lung cancer includes 2 major clinicopathological categories: small cell lung cancer and NSCLC. The latter accounts for approximately 85% of all cases of lung cancer, and NSCLC tumors consist mainly of 3 subtypes: LUAD, LUSQ, and large cell carcinoma. 2 In patients with LUAD, currently developed treatment strategies (eg, epidermal growth factor receptor tyrosine kinase inhibitors, inhibitors of anaplastic lymphoma kinase, and immune checkpoint inhibitors) have dramatically improved OS rates in patients. [3] [4] [5] [6] In contrast, in patients with LUSQ, the lack of early diagnostic tools and effective treatment protocols has resulted in a poor OS rate in patients with LUSQ. 7, 8 Therefore, identification of therapeutic target molecules is essential for achieving improved outcomes in patients with LUSQ.
MicroRNAs are a class of small, noncoding RNAs (19-22 nt in length). These molecules regulate gene expression by repressing translation or cleaving RNA transcripts in a sequence-dependent manner. 9 Interestingly, a single miRNA species could regulate a vast number of protein-coding and noncoding RNA transcripts. 10 In human disease cells, aberrantly expressed miRNAs trigger the failure of orderly and controlled RNA networks. 11 Numerous studies have shown that aberrant expression of miRNAs and dysregulated RNA networks are deeply involved in human diseases, including cancer. [12] [13] [14] [15] [16] Through our continuing work, we have identified antitumor miRNAs and their target oncogenic genes in LUSQ. [17] [18] [19] [20] [21] [22] Moreover, detailed analyses of our original miRNA expression signatures by RNA sequencing have revealed that passenger strands of miRNAs actually act as antitumor miRNAs and are involved in cancer pathogenesis. [23] [24] [25] Additionally, our recent studies showed that both strands of the miR-144 duplex (ie, the passenger strand miR-144-5p and the guide strand miR-144-3p) are downregulated in bladder cancer and RCC tissues and act as antitumor miRNAs. 26, 27 The involvement of both strands of the miRNA duplex in cancer pathogenesis is a new concept for cancer research.
Several cohort analyses by TCGA database have indicated that low expression of miR-144-5p predicts poor prognosis in patients with LUSQ (OS, P = 0.026; DFS, P = 0.023). Thus, both strands of the miR-144 duplex are involved in LUSQ molecular pathogenesis. Here, we aimed to verify that miR-144-5p and miR-144-3p possess antitumor functions. We also sought to identify their molecular targets, thereby revealing new details of LUSQ pathogenesis.
| MATERIAL S AND ME THODS

| Clinical specimen collection, cell lines, and cell culture
The present study was approved by the Bioethics Committee of Kagoshima University Hospital (Kagoshima, Japan) (approval nos edition. 28 The clinicopathological features of the patients are shown in Table 1 . The procedure for RNA extraction from formalin-fixed, paraffin-embedded specimens was described in previous studies. 19 In addition, we evaluated 2 LUSQ cell lines (EBC-1 and SK-MES-1), obtained from the Japanese Cancer Research Resources Bank (Osaka, Japan) and ATCC (Manassas, VA, USA), respectively. Cell culture, extraction of total RNA, and extraction of protein were carried out as described in our earlier reports.
18,19,21
| Quantitative real-time RT-PCR
The procedure for qRT-PCR has been described previously. 18, 22, 29 The expression levels of miRNAs were analyzed by TaqMan After a 48-hour incubation period, miRNAs were isolated by immunoprecipitation using a microRNA Isolation Kit for Human Ago2 (Wako, Osaka, Japan). We then assessed the expression of Ago2-conjugated miRNAs by qRT-PCR, as described in previous studies.
30,31
| Cell proliferation, migration, and invasion assays
Protocols for determining cell proliferation, migration, and invasion were described previously.
17,22
| Identification of putative target genes regulated by miR-144-5p and miR-144-3p in LUSQ cells
Gene expression analyses by oligo microarray and in silico analyses were used to identify putative target genes regulated by miR-144-5p and miR-144-3p.
The microarray data were deposited in the GEO repository under accession number GSE115801. Putative target genes having binding sites for miR-144-5p and miR-144-3p were detected by TargetScanHuman version 7.2 (http://www.targetscan.org/vert_72/). The GEO database (GSE19188) was used for assessment of the association between target genes and expression of NSCLC clinical specimens. Identification of miR-144-5p and miR-144-3p
target genes was carried out as described in Figure S1 .
| Clinical database analysis
The clinical significance of miRNAs and their target genes in LUSQ was investigated with TCGA database (https://tcga-data.nci.nih.
gov/tcga/). The gene expression and clinical data were retrieved from cBioPortal (http://www.cbioportal.org/) and OncoLnc (http:// www.oncolnc.org) (data downloaded on April 28, 2018).
31-33
| Plasmid construction and dual-luciferase reporter assay
Wild-type or deletion-type sequences targeted by miR-144-5p and miR-144-3p were inserted into the psiCHECK-2 vector (C8021;
Promega, Madison, WI, USA). 
F I G U R E 1 Expression levels of miR-144-5p and miR-144-3p in clinical lung squamous cell carcinoma (LUSQ) specimens and cell lines, and analysis of the expression levels of miR-144-5p and miR-144-3p in patients with LUSQ using The Cancer Genome Atlas (TCGA) database. A, Expression levels of miR-144-5p in clinical specimens and cell lines (EBC-1 and SK-MES-1). B, Expression levels of miR-144-3p in clinical specimens and cell lines (EBC-1 and SK-MES-1). Data were normalized to
| Western blot analysis and immunohistochemistry
The procedures for western blotting and immunohistochemistry were described previously. 21, 22 Membranes were immunoblotted with monoclonal anti-NCS1 Abs (1:1000 dilution; ab129166; Abcam, Cambridge, UK) and monoclonal anti-GAPDH Abs (1:20 000 dilution; MAB374; EMD Millipore, Billerica, MA, USA).
Immunohistochemistry was carried out with a VECTASTAIN Universal Elite ABC Kit (catalog no. PK-6200; Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol. Primary rabbit mAbs against NCS1 (ab129166; Abcam) were used at a 1:100 dilution at 4°C overnight. The characteristics of patients included in the tissue microarray are described in Table 2 . The procedure for immunohistochemistry was described previously. 18, 22, 34 F I G U R E 2 Functional assays of miR-144-5p and miR-144-3p in lung squamous cell carcinoma cell lines. A, Cell proliferation was determined by XTT assays 72 hours after transfection with miR-144-5p and miR-144-3p. B, Cell migration was measured by wound healing assays. C, Cell invasion was determined by Matrigel invasion assays. Cell proliferation, migration, and invasion were significantly suppressed in miR-144-5p and miR-144-3p transfectants compared with those in mock and control transfectants. *P < 0.001 Figure 1D ). Low expression of miR-144-3p also tended to predict poor prognosis compared with high expression of miR-144-3p in LUSQ patients (5-year OS, P = 0.072; 5-year DFS, P = 0.072; Figure 1E ). 
| Ectopic expression of
| Incorporation of miR-144-5p and miR-144-3p into RISC in LUSQ cells
To verify whether the miR-144-5p passenger strand could be incor- Figure 3A .
In EBC-1 cells, miR-144-5p transfectants showed higher expression levels of miR-144-5p than did mock transfectants or miR-control or miR-144-3p (P < 0.001) transfectants ( Figure 3B ). Similarly, after miR-144-3p transfection, we detected miR-144-3p using Ago2 immunoprecipitation (P < 0.001; Figure 3C ).
| Identification of putative target genes regulated by miR-144-5p and miR-144-3p in LUSQ cells
Next, we aimed to identify miR-144-5p and miR-144-3p target genes. To this end, we undertook a combination of in silico and genome-wide gene expression analyses, as shown in Figure S1 .
Using TargetScanHuman database analysis, 1785 and 3776 putative target genes were found to have binding sites for miR-144-5p and miR-144-3p, respectively. Among these genes, we selected genes that were upregulated in NSCLC clinical expression profiles from the GEO database (accession no. GSE19188).
Next, we merged gene expression analysis data using miR-144-5p-or miR-144-3p-transfected SK-MES-1 cells (GEO accession no. GSE115801). This analysis yielded miR-144-5p-and miR-144-3p-
controlled genes (n = 13 and 15, respectively) in LUSQ cells (Table   S1 and S2). Overall, 3 putative target genes (NCS1, SLC44A5, and MARCKS) were coordinately regulated by both miR-144-5p and miR-144-3p (Table 3) .
TA B L E 3 Common putative target genes regulated by miR-144-5p and miR-144-3p in lung squamous cell carcinoma cells
Entrez gene ID
The TCGA database analysis showed that high NCS1 expression significantly predicted a poor prognosis in patients with LUSQ (5-year OS, P = 0.013; 5-year DFS, P = 0.048; Figure 4A ). Subsequently, we focused on NCS1 and validated the functional significance of LUSQ cells. 
F I G U R E 6
Effects of NCS1 silencing in lung squamous cell carcinoma cell lines. A, mRNA expression of NCS1 72 hours after transfection with si-NCS1 using GAPDH as an internal control. B, NCS1 protein expression by western blot analysis 72 hours after transfection with si-NCS1-1 and si-NCS1-2 in EBC-1 and SK-MES-1 cell lines. GAPDH was used as a loading control. C, Cell proliferation was identified by XTT assays 72 hours after transfection with si-NCS1-1 and si-NCS1-2. D, Cell migration was measured by wound healing assays. E, Cell invasion was determined by Matrigel invasion assays. *P < 0.001
| NCS1 knockdown inhibited cell proliferation, migration, and invasion in LUSQ cells
We examined the effects of NCS1 knockdown in EBC-1 and SK-MES-1 cells using 2 types of si-NCS1 oligos: si-NCS1-1 and si-NCS1-2.
Both siRNAs effectively downregulated NCS1 mRNA and NCS1 protein expression ( Figure 6A,B) .
Cancer cell proliferation, migration, and invasive abilities were markedly inhibited by si-NCS1 transfection compared with those in mock or control EBC-1 and SK-MES-1 cells (Figure 6C-E) .
| Expression of NCS1 in LUSQ clinical specimens and its clinical significance
Immunohistochemical analyses of LUSQ clinical specimens indicated that NCS1 protein was strongly expressed in LUSQ cells, but showed infrequent and weak expression in normal lung cells (Table 2 and Figure 7 ).
Finally, univariate and multivariate Cox hazard regression analyses were used to evaluate the clinical significance of NCS1 expression for OS in patients with LUSQ. Multivariate analysis showed that NCS1 expression was an independent predictive factor for OS (hazard ratio = 1.508, P = 0.007; Figure 8 ).
| D ISCUSS I ON
In our previous studies, we showed that both strands of the miR-145 duplex (the guide strand miR-145-5p and the passenger strand miR-145-3p) were significantly downregulated in cancer tissues. These miRNAs were also found to have antitumor functions, and their targets were involved in NSCLC pathogenesis. 20, 35 Thus, research focusing on both strands of the miRNA duplex is important for improving outcomes in cancer.
In this study, we found that both miR-144-5p and miR-144-3p
had tumor-suppressing effects in LUSQ cells and controlled several oncogenes. In an analysis of previous studies of the functional significance of the miR-144 duplex, the antitumor function of miR- 26, 27 In our studies, we focused on both strands of the miR-144 duplex and investigated the antitumor functions and targets of the duplex in cancer cells. 26, 27 Our previous studies showed that both strands of the miR-144 duplex had antitumor functions in bladder cancer and RCC and that both miRNAs coordinately targeted CCNE1/CCNE2 and SDC3, respectively. 26, 27 This study is the third paper reporting the antitumor functions of both strands of the miR-144 duplex in cancer cells. Importantly, low expression of miR-144-5p
and miR-144-3p significantly predicted short survival in patients with RCC. 27 Moreover, high expression of the oncogenic genes controlled by these miRNAs also predicted short survival in patients with RCC, suggesting that the miR-144 duplex and its targets were deeply involved in RCC pathogenesis. 27 In this study, 3 genes (NCS1, SLC44A5, and MARCKS) were found to be coordinately controlled by both miR-144-5p and miR-144-3p in LUSQ cells. MARCKS is a major substrate of protein kinase C. 42 Recent studies have shown that MARCKS plays a pivotal role in cancer development and progression. 42 Moreover, in lung cancer, aberrant MARCKS expression was detected in clinical specimens, and MARCKS expression was implicated in this disease. 43, 44 Among the 3 targets, we focused on NCS1 because its aberrant expression significantly predicted poor prognosis in patients.
The NCS1 protein is a member of the NCS family, which harbors a functional Ca 2+ binding domain and N-terminally myristoylated site. 45, 46 Previous studies have reported that NCS1 is a multifunctional protein involved in exocytosis, neurite outgrowth, neuroprotection, axonal regeneration, and nuclear Ca 2+ regulation. 45, 46 Furthermore, NCS1 interacts with various proteins to control their functions. 45, 46 For example, NCS1 interacts with D2R and inhibits D2R-mediated signaling pathways. 47 Interestingly, activation of D2R-mediated signaling suppresses lung cancer aggressiveness. 48 Moreover, aberrant expression of NCS1 could interfere with D2R-mediated signaling and might be involved in LUSQ cell progression.
Our functional assays showed that inhibition of NCS1 by siRNA suppressed cancer cell migration and invasion in LUSQ cells.
Moreover, in multivariate Cox proportional hazards regression analysis, expression of NCS1 predicted poor prognosis in patients with LUSQ. Another study showed that overexpression of NCS1 promoted cell invasion and migration in breast cancer cells and that NCS1 overexpression was associated with poor prognosis in these patients. 49 These findings indicate that aberrantly expressed NCS1
is involved in cancer cell aggressiveness. Thus, NCS1 could be a novel diagnostic and therapeutic target for patients with LUSQ.
In conclusion, genes coordinately controlled by the miR-144 duplex (miR-144-5p and miR-144-3p) were found to be related to LUSQ pathogenesis. Our findings describing the involvement of the passenger strand miR-144-5p are the first report of this phenomenon in LUSQ pathogenesis. NCS1 expression was directly regulated by the miR-144 duplex in LUSQ cells. Aberrantly expressed NCS1 enhanced LUSQ cell aggressiveness. Thus, elucidation of antitumor miRNAs controlling RNA networks could provide novel prognostic markers and therapeutic targets for this disease.
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